Arcadia Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Thomas Schaefer

Chief executive officer

US$381.8k

Total compensation

CEO salary percentage	68.1%
CEO tenure	2.3yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	6.5yrs

Recent management updates

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

CEO Compensation Analysis

How has Thomas Schaefer's remuneration changed compared to Arcadia Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$382k	US$260k	-US$13m

Compensation vs Market: Thomas's total compensation ($USD381.84K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.

CEO

Thomas Schaefer (48 yo)

2.3yrs

Tenure

US$381,838

Compensation

Mr. Thomas J. Schaefer serves as Chief Executive Officer and President of Arcadia Biosciences, Inc. from July 05, 2024 and is its Director since August 1, 2024. He served as Chief Financial Officer of Arca...

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Schaefer	CEO, President & Director	less than a year	US$381.84k	0.16% $ 8.8k
Gregory Waller	Independent Director	7.4yrs	US$68.32k	0% $ 0
Lilian Murray	Independent Director	6.4yrs	US$68.32k	0.016% $ 890.1
Albert Bolles	Independent Director	6.5yrs	US$50.32k	0% $ 0
Kevin Comcowich	Independent Chair of the Board	8.1yrs	US$99.09k	0.037% $ 2.1k
Amy Yoder	Independent Director	7.3yrs	US$64.82k	0% $ 0
Deborah Carosella	Independent Director	3.8yrs	US$57.48k	0% $ 0

6.5yrs

Average Tenure

65yo

Average Age

Experienced Board: RKDA's board of directors are considered experienced (6.5 years average tenure).

Arcadia Biosciences Management

Management criteria checks 2/4

Key information

Recent management updates

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

Insufficient new directors

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Arcadia Biosciences, Inc. Announces CFO Changes

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Recent updates

Arcadia Biosciences, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus EPS estimates fall by 27%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcadia Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Consensus revenue estimates decrease by 17%, EPS upgraded

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

Arcadia Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

New 90-day high: US$3.58

Arcadia Biosciences, Inc. announced that it expects to receive $25.146633 million in funding

New 90-day high: US$3.45